Netherton Study - Boehringer-Ingelheim
A study to test whether an investigational medication helps patients with Netherton syndrome1
Safety and efficacy have not been established.
Netherton syndrome is a rare condition. Patients have skin inflammation, a unique hair pattern called bamboo hair, and other symptoms.
If you have been diagnosed with Netherton syndrome and want to participate in this clinical study, you have to meet these conditions (eligibility criteria)1:
- Male or female 18 years and older
- Confirmed Netherton syndrome diagnosis (causative SPINK5 mutations)
- Moderate to severe skin redness
- Avoid certain kinds of topical medicines for 1 week before the study
- Avoid certain other medications or phototherapy for 4 weeks before the study
- Avoid systemic antibiotics for 2 weeks before the study
- Avoid investigational drugs for a certain period before the study
- Avoid biologics or immunoglobulins for a certain period before the study
- No prior exposure to an interleukin 36 receptor (IL-36R) inhibitor biologic
- Additional inclusion and exclusion criteria
When participating in a clinical trial, you will be expected to take the study medication and follow the instructions provided. You will need to attend regularly scheduled visits, have lab tests, and answer questionnaires. This process aims to gather more information about you, your medical condition, and your experience in the study.
For more information:
Phone: 1-800-243-0127 (select option 2, then select option 4)
Click here to learn more about the EVASAYILTM trial.
Participation in a clinical trial is voluntary, and you may withdraw from the study at any time with or without any given reason. You can read more about the study and your participation in the material you will be given during your screening visit.
Study sponsor: Boehringer Ingelheim. Information prepared for residents of the United States and Puerto Rico. The information provided is subject to alterations at any time a In the United States, the minimum age is 18 years old.
1. ClinicalTrials.gov identifier: NCT05856526. 2. Petrova E, Hovnanian A. Expert Opin Orphan Drugs. 2020;8:455-487. Copyright © 2023 Boehringer Ingelheim
Pharmaceuticals, Inc. All rights reserved.